Connecting the DotBodies
DotBio launches with a platform to develop humanized stable domain antibodies
Cancer play DotBio Pte. Ltd. launched this week with a screening platform to discover and develop products based on humanized domain antibodies that could be more stable and easier to manufacture than other domain antibodies.
DotBio spun out of Nanyang Technological University (NTU) in Singapore in 2017 with exclusive rights to domain antibody technology and domain antibodies, called DotBodies, against undisclosed targets